DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Prolia (Denosumab) - Published Studies

 
 



Prolia Related Published Studies

Well-designed clinical trials related to Prolia (Denosumab)

Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). [2014]

Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. [2014]

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. [2012]

Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. [2012]

Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis. [2012]

Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association? [2012]

Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal. [2011.11.01]

Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association? [2011.09.03]

Effects of denosumab on fracture and bone mineral density by level of kidney function. [2011.08]

Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. [2011.06]

Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. [2011.04]

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. [2011.03.20]

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. [2011.03.05]

Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. [2011.03]

A randomized, double-blind, placebo-controlled, single-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of denosumab administered subcutaneously to postmenopausal Japanese women. [2011]

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. [2011]

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. [2010.12.10]

Clinical use of denosumab for the treatment for postmenopausal osteoporosis. [2010.12]

Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. [2010.10]

Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. [2010.07]

Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. [2010.05]

Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. [2010.04]

Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis. [2010.04]

Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. [2010.03]

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. [2010.01]

Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. [2010]

Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis. [2010]

Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. [2010]

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. [2010]

Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. [2009.12]

Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. [2009.11]

Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. [2009.10]

Denosumab in men receiving androgen-deprivation therapy for prostate cancer. [2009.08.20]

Denosumab for prevention of fractures in postmenopausal women with osteoporosis. [2009.08.20]

Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. [2009.08]

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. [2009.04.01]

Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. [2009.01]

Is twice-yearly denosumab beneficial in postmenopausal women with osteopenia but no history of fracture? [2008.12]

Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. [2008.10.20]

Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. [2008.10.15]

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial. [2008.08]

Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients. [2008.08]

Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate. [2008.07]

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. [2008.06]

Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. [2008.05]

Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. [2007.12]

Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. [2007.10.01]

Well-designed clinical trials possibly related to Prolia (Denosumab)

Ranking antireabsorptive agents to prevent vertebral fractures in postmenopausal osteoporosis by mixed treatment comparison meta-analysis. [2013]

Adjuvant therapy with bone-targeted agents. [2011.09]

Estimating minimally important differences for the worst pain rating of the Brief Pain Inventory-Short Form. [2011.03]

Estimating minimally important differences for the worst pain rating of the Brief Pain Inventory-Short Form. [2011]

Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. [2011]

Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. [2010.05]

Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. [2010]

Update on the treatment of post-menopausal osteoporosis. [2008]

Other research related to Prolia (Denosumab)

Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the Denosumab Adherence Preference Satisfaction study. [2014]

Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis. [2014]

Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. [2014]

Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. [2013]

Effects of denosumab on cortical and trabecular microarchitecture: evidences from clinical studies. [2013]

A new antiresorptive approach to the treatment of fragility fractures: long-term efficacy and safety of denosumab. [2013]

Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study. [2013]

Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. [2013]

Incidence and risk of denosumab-related hypocalcemia in cancer patients: a systematic review and pooled analysis of randomized controlled studies. [2013]

Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. [2013]

One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. [2013]

Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. [2013]

Efficacy and safety of denosumab versus zoledronic acid in patients with bone metastases: a systematic review and meta-analysis. [2013]

Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients. [2012]

Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. [2012]

Denosumab for the prevention of skeletal-related events in patients with bone metastasis from solid tumor. [2012]

Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis. [2012]

Denosumab and the current status of bone-modifying drugs in breast cancer. [2012]

Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. [2012]

Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. [2011.11.16]

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. [2011.11.15]

Denosumab for the reduction of bone loss in postmenopausal osteoporosis: a review. [2011.11]

A randomized, double-blind, placebo-controlled, single-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of denosumab administered subcutaneously to postmenopausal Japanese women. [2011.11]

Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. [2011.10.04]

Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases. [2011.10]

Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. [2011.09.17]

Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis. [2011.09.17]

Denosumab: benefits of RANK ligand inhibition in cancer patients. [2011.09]

[Denosumab as the potent therapeutic agent against Paget's disease of bone]. [2011.08]

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. [2011.05]

Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases. [2011]

Effects of denosumab on fracture and bone mineral density by level of kidney function. [2011]

Denosumab for the treatment of osteoporosis. [2010.12]

Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. [2010.09.13]

Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. [2010.09.09]

Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. [2010.08]

Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women. [2010.07]

Treatment of osteoporosis with denosumab. [2010.06]

Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. [2010.03]

Denosumab--an emerging treatment for postmenopausal osteoporosis. [2010.03]

Comparison of the Effect of Denosumab and Alendronate on Bone Mineral Density and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial. [2009.12.14]

[From orthoclone to denosumab, the fast growing market of monoclonal antibodies] [2009.12]

Denosumab: the era of targeted therapies in bone metastatic diseases. [2009.11]

Denosumab. [2009.05]

Other possibly related research studies

Osteonecrosis of the jaws induced by anti-RANK ligand therapy. [2010.04]

Safety considerations for use of bone-targeted agents in patients with cancer. [2010.06]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015